A game theoretic approach to robust filtering

A game theoretic approach to the filtering or smoothing problem is presented. A family of stationary information carrying processes and generalized models for the noise channel and the filter is considered. Sufficient conditions for the existence of saddle-point type solutions are stated. In addition, the solution for a special case of noise channel, a family of information carrying processes, and a nonlinear filter are found

Outlier resistant filtering and smoothing

AbstractWe consider a stationary Gaussian information process transmitted through an additive noise channel. We assume that the noise and information processes are mutually independent, and we model the noise process as nominally Gaussian with additive outliers. For the above system model, we first develop a theory for outlier resistant filtering and smoothing operations. We then design specific such nonlinear operations, and we study their performance. The performance criteria are the asymptotic mean squared error at the Gaussian nominal model, the breakdown point, and the influence function. We find that the proposed operations combine excellent performance at the nominal model with strong resistance to outliers

Urban Air Mobility Vehicle and Fleet-level Life-Cycle Assessment Using a System-of-Systems Approach

Can Urban Air Mobility (UAM) systems constitute viable and sustainable mobility solutions? This question has increasingly been concerning scientists, companies, policy makers, and authorities as more and more UAM vehicle concepts are seeing the light of day. In order to come closer to answering this question and to demonstrate the dependencies and impacts of the numerous parameters used to describe a highly complex system of a fleet of UAM vehicles operating in an urban environment, this paper employs a System of Systems (SoS) approach. A collaborative SoS framework with an agent-based simulation is introduced, which connects the UAM vehicle design, fleet performance, vertiport network, and re-energizing infrastructure with a Life-Cycle Assessment (LCA). The framework is used to simulate four exemplary UAM fleet-operation scenarios based on two cities and two operational modes, namely urban and suburban operations. Different vehicle design configurations, e.g. multirotor and lift + cruise vehicles, are evaluated in each scenario based on respectively realistic Concepts of Operations (CONOPS). Additionally, two different points in time, namely 2025 and 2050, are considered and assessed for powering the vehicles by taking into account the characteristics of batteries as well as the underlying electricity mix for their operation. Lithium nickel manganese cobalt oxide battery and lithium-sulfur (Li-S) batteries are considered. The SoS framework helps to asses various UAM metrics such as the average wait time for a passenger, the ideal number of aircraft needed for transporting all passengers within given time, the energy required on a vehicle and fleet level, sustainability metrics, e.g. the global warming potential associated with the energy carriers and many more. The capability to explore a wide design space and to visualize the dependencies between the system parameters and their impacts on different SoS metrics provides stakeholders with a helpful tool for their decision making

A Unified Multi-Functional Dynamic Spectrum Access Framework: Tutorial, Theory and Multi-GHz Wideband Testbed

Dynamic spectrum access is a must-have ingredient for future sensors that are ideally cognitive. The goal of this paper is a tutorial treatment of wideband cognitive radio and radar—a convergence of (1) algorithms survey, (2) hardware platforms survey, (3) challenges for multi-function (radar/communications) multi-GHz front end, (4) compressed sensing for multi-GHz waveforms—revolutionary A/D, (5) machine learning for cognitive radio/radar, (6) quickest detection, and (7) overlay/underlay cognitive radio waveforms. One focus of this paper is to address the multi-GHz front end, which is the challenge for the next-generation cognitive sensors. The unifying theme of this paper is to spell out the convergence for cognitive radio, radar, and anti-jamming. Moore’s law drives the system functions into digital parts. From a system viewpoint, this paper gives the first comprehensive treatment for the functions and the challenges of this multi-function (wideband) system. This paper brings together the inter-disciplinary knowledge

Correction: A european spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics (PLoS ONE (2016) 11:9 (e0162866) DOI: 10.1371/journal.pone.0162866)

The thirty-Third author's name is spelled incorrectly. The correct name is: Jadranka Sertić

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/ or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective

A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective